Tamoxifen failure in medullary thyroid carcinoma.
We report the results of short-term tamoxifen treatment (20 mg two times a day orally) in 2 patients with metastatic medullary thyroid carcinoma. Patient A had a rapid tumor progression with development of Cushing's syndrome before initiation of tamoxifen treatment. Patient B had a slowly progressive course. In both cases, neither clinical nor biochemical improvement were observed, after 1 and 3 months of tamoxifen therapy, respectively.
García-Pascual
L
L
Division of Endocrinology, Hospital Mutua de Terrassa, University of Barcelona, Spain.
Millán
M
M
Anglada
J
J
Garau
J
J
D000328:Adult; D018276:Carcinoma, Medullary / Q000188:drug therapy*; D005260:Female; D006801:Humans; D013629:Tamoxifen / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D017211:Treatment Failure
D013629:Tamoxifen